Advanced Search

 

Study ID Status Title Patient Level Data
104798 Completed A phase II study to assess the efficacy, immunogenicity and safety of GSK Biologicals' HPV-16/18 L1 VLP AS04 (Cervarix TM) vaccine administered intramuscularly according to a 0, 1, 6 month schedule in healthy Japanese female subjects aged 20 - 25 years. Study Listed on ClinicalStudyDataRequest.com
104820 Completed A study to evaluate safety, immunogenicity and efficacy of GSK Biologicals HPV-16/18 L1/AS04 vaccine administered intramuscularly according to a three-dose schedule (0, 1, 6 month) in healthy adult female subjects aged 26 years and above Study Listed on ClinicalStudyDataRequest.com
104847 Completed A Study to Assess the Interaction of SB-480848 with Aspirin and/or Clopidogrel
104858 Completed A phase III, single-blind, randomized study to evaluate the immunogenicity and safety of Fluarix® (GSK Biologicals) compared with Fluzone® (Aventis Pasteur/Sanofi) administered intramuscularly in children (6 months and older) Study Listed on ClinicalStudyDataRequest.com
104864/111127 Completed An open-label, multicenter, non-comparative, Phase II study of oral topotecan in combination with bevacizumab for second-line treatment in subjects with relapsed small-cell Lung Cancer (SCLC)
104864/201 Completed A Phase III, Open-Label, Multicenter, Randomized, Comparative Study of Topotecan, Ara-C and G-CSF (TAG) versus Idarubicin, Ara-C and G-CSF (IDAG) in MDS Patients with RAEB (High-Risk), RAEB-t or in Patients with AML from a Preceding Phase of MDS
104864/250 Completed Phase I/II study of oral topotecan and intravenous paclitaxel in patients with advanced non-small cell lung cancer (phases I and II) and other advanced solid tumors (phase I only)
104864/386 Completed An open-label, multicenter, randomized, phase II study of 5-day oral topotecan vs. 21-day oral topotecan vs. CPT-11 (Irinotecan) for second-line therapy in patients with colorectal carcinoma
104864/396 Completed An open-label, multicentre, randomised, phase III comparator study of oral topotecan versus intravenous topotecan for second-line therapy in patients with SCLC who have relapsed greater than or equal to 90 days after completion of first-line therapy
104864/405 Completed An Open Label, Multicenter, Randomized, Phase II Study of Topotecan and Paclitaxel vs. Etoposide/Cisplatin as First Line Treatment in Patients with Extensive Disease Small Cell Lung Cancer
104864/410 Completed A randomised open-label multicentre Phase II study to evaluate the safety and efficacy of intravenous topotecan given with either cisplatin or etoposide every 21 days as first-line therapy in patients with extensive-disease (ED) small-cell lung cancer
104864/435 Completed A Phase II Study of Topotecan and Paclitaxel as First-Line Treatment in Patients with Extensive Disease Small Cell Lung Cancer
104864/438 Completed Phase I Study of Oral Topotecan in Patients with Hematological Myeloid Malignancies
104864/478 Completed An Open-Label, Multicentre, Randomised, Phase III Comparator Study of Active Symptom Control alone or in Combination with Oral Topotecan in Patients with Relapsed Resistant SCLC
104864/502 Completed An Open-Label, Multicenter, Randomized, Phase II Study of Oral Topotecan Daily x 5 Days vs. Oral Topotecan 5 Days On, 2 Days Off for 3 Weeks for Second-Line Treatment in Patients with Recurrent, Locally Advanced or Metastatic Cervical Cancer
104864/507 Completed Phase I Study of the Effect of Oral Cyclosporin A on the Pharmacokinetics of Oral Topotecan
104864/511 Completed A Phase I open label study to assess the safety, tolerability, and efficacy of oral etoposide and oral topotecan administered in combination to patients with small-cell lung cancer who have not previously received chemotherapy
104864/517 Terminated A Phase I study of oral topotecan as a radiosensitizing agent in patients with rectal cancer
104864/535 Completed A Phase II Trial of Twice Daily Oral Topotecan as a Radiation Sensitizer with Twice Daily Radiotherapy for Newly Diagnosed Small Cell Lung Cancer
104864/612 Completed A prospective, open label phase II study to evaluate the efficacy and safety of topotecan (Hycamtin) in combination with carboplatin as first-line chemotherapy in patients with ovarian cancer.
104864/623 Completed An Open Label, Multicenter, Non-Comparative Phase II Study of Weekly Intravenous Vinorelbine and Topotecan in Chemotherapy-Nave Patients with Advanced Non-Small Cell Lung Cancer
104864/627 Completed An Open-label, Multicenter, Non-Comparative Phase II Study of the Combination of Intravenous Topotecan and Gemcitabine Administered Once Weekly for Three Weeks Every 28 Days as Second-line Treatment in Patients with Recurrent Platinum Sensitive Ovarian Cancer
104864/902 Completed An Open-Label, Single-Arm, Phase II Study of IV Weekly (Days 1 and 8 every 21 days) HYCAMTIN in Combination with Carboplatin (Day 1 every 21 days) as Second-Line Therapy in Subjects with Potentially Platinum-Sensitive Relapsed Ovarian Cancer
104864/903 Completed An open-label phase II study of weekly intravenous Hycamtin and carboplatin as first-line treatment of chemonaive subjects with Extensive Disease Small Cell lung Cancer
104864-A/387 Completed An Open-Label, Multicentre, Randomised, Phase III Study Comparing Oral Topotecan to Intravenous Docetaxel in Patients with Pretreated Advanced Non Small Cell Lung Cancer

 

 

For more information on this register please email GSKClinicalSupportHD@gsk.com

GSK-sponsored clinical studies are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.
GSK-sponsored clinical trials are those for which GSK is ultimately responsible for all aspects of the study even if some or all of these activities are transferred to another party.

ClinicalTrial.gov is a database that provides summary protocol information for ongoing clinical trials.

IFPMA.org is a search portal provided by the International Federation of Pharamceutical Manufacturers & Associations (IFPMA).

This portal provides a single entry point to search for industry sponsored clinical trials which are on existing registers and databases.

EU Clinical Trials Register is a database of all clinical trials commencing in the European Community from 1 May 2004 onwards. It has been established in accordance with Directive 2001/20/EC.